Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

729 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alzheimer's disease progression by geographical region in a clinical trial setting.
Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Henley DB, et al. Among authors: miller ds. Alzheimers Res Ther. 2015 Jun 25;7(1):43. doi: 10.1186/s13195-015-0127-0. eCollection 2015. Alzheimers Res Ther. 2015. PMID: 26120369 Free PMC article.
Global issues in drug development for Alzheimer's disease.
Doody RS, Cole PE, Miller DS, Siemers E, Black R, Feldman H, Schindler R, Graham S, Heath T, Khachaturian AS, Evans R, Carrillo MC. Doody RS, et al. Among authors: miller ds. Alzheimers Dement. 2011 Mar;7(2):197-207. doi: 10.1016/j.jalz.2011.01.001. Alzheimers Dement. 2011. PMID: 21414556
Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.
Gordon MF, Lenderking WR, Duhig A, Chandler J, Lundy JJ, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S, Frank L; Patient-Reported Outcome Consortium's Cognition Working Group. Gordon MF, et al. Among authors: miller ds. Alzheimers Dement. 2016 Jan;12(1):75-84. doi: 10.1016/j.jalz.2015.04.008. Epub 2015 Jun 13. Alzheimers Dement. 2016. PMID: 26079412 Review.
Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.
Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Grill JD, et al. Among authors: miller ds. Alzheimers Res Ther. 2015 Jun 25;7(1):39. doi: 10.1186/s13195-015-0122-5. eCollection 2015. Alzheimers Res Ther. 2015. PMID: 26120368 Free PMC article.
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanctôt KL, Miller DS, Mortby ME, Onyike CU, Rosenberg PB, Smith EE, Smith GS, Sultzer DL, Lyketsos C; NPS Professional Interest Area of the International Society of to Advance Alzheimer’s Research and Treatment (NPS-PIA of ISTAART). Ismail Z, et al. Among authors: miller ds. J Alzheimers Dis. 2017;56(3):929-938. doi: 10.3233/JAD-160979. J Alzheimers Dis. 2017. PMID: 28059789 Free PMC article.
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.
Rabinovici GD, Carrillo MC, Forman M, DeSanti S, Miller DS, Kozauer N, Petersen RC, Randolph C, Knopman DS, Smith EE, Isaac M, Mattsson N, Bain LJ, Hendrix JA, Sims JR. Rabinovici GD, et al. Among authors: miller ds. Alzheimers Dement (N Y). 2016 Sep 20;3(1):83-91. doi: 10.1016/j.trci.2016.09.002. eCollection 2017 Jan. Alzheimers Dement (N Y). 2016. PMID: 29067320 Free PMC article. Review.
The pathway to secondary prevention of Alzheimer's disease.
McDade E, Bednar MM, Brashear HR, Miller DS, Maruff P, Randolph C, Ismail Z, Carrillo MC, Weber CJ, Bain LJ, Hake AM. McDade E, et al. Among authors: miller ds. Alzheimers Dement (N Y). 2020 Aug 27;6(1):e12069. doi: 10.1002/trc2.12069. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32885024 Free PMC article.
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Rentz DM, Aisen PS, Atri A, Hitchcock J, Irizarry M, Landen J, Matthews BR, Miller DS, Mahinrad S, Napoli S, Okhravi HR, Petersen RC, Siemers ER, Weber CJ, Weisman DC, Carrillo MC. Rentz DM, et al. Among authors: miller ds. Alzheimers Dement. 2024 Nov;20(11):8162-8171. doi: 10.1002/alz.14199. Epub 2024 Sep 22. Alzheimers Dement. 2024. PMID: 39306695 Free PMC article.
Scales as outcome measures for Alzheimer's disease.
Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y. Black R, et al. Among authors: miller ds. Alzheimers Dement. 2009 Jul;5(4):324-39. doi: 10.1016/j.jalz.2009.05.667. Alzheimers Dement. 2009. PMID: 19560103
729 results